Apollomics Inc. (NASDAQ:APLM - Get Free Report) COO Yi-Kuei Chen purchased 20,000 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were bought at an average cost of $15.00 per share, with a total value of $300,000.00. Following the purchase, the chief operating officer directly owned 121,248 shares of the company's stock, valued at approximately $1,818,720. This represents a 19.75% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink.
Apollomics Price Performance
Shares of NASDAQ:APLM opened at $23.36 on Tuesday. Apollomics Inc. has a 52-week low of $3.66 and a 52-week high of $42.12. The business's 50 day moving average is $18.24 and its 200 day moving average is $17.30.
Institutional Investors Weigh In On Apollomics
A hedge fund recently bought a new position in Apollomics stock. Kestra Advisory Services LLC acquired a new stake in shares of Apollomics Inc. (NASDAQ:APLM - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 4,380 shares of the company's stock, valued at approximately $82,000. Kestra Advisory Services LLC owned approximately 0.40% of Apollomics at the end of the most recent reporting period. 19.13% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Separately, Weiss Ratings downgraded Apollomics from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, July 28th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Apollomics currently has a consensus rating of "Sell".
Get Our Latest Analysis on APLM
About Apollomics
(
Get Free Report)
Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company's research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.
Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
